Lite Strategy, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Lite Strategy, Inc. (LITS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 0 shares for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2020-11-10
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2020-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2020-06-30 was 0.00 shares.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2020-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-12-31 was 30.81K shares.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 557.89K shares, a 57.66% increase from fiscal 2019.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2019 was 353.85K shares, a 48.52% increase from fiscal 2018.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2018 was 238.25K shares, a 334.71% increase from fiscal 2017.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2017 was 54.81K shares, a 2.94% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2020-09-30 | 0.00 shares 10-Q · filed 2020-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-10 | 0.00 shares derived: sum of 3 quarters · filed 2020-11-10 | 30.81K shares derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09 | 0.00 shares derived: sum of 2 quarters · filed 2020-09-09 | 30.81K shares derived: sum of 3 quarters · filed 2020-09-09 | 557.89K shares 10-K · filed 2020-09-09 |
| 2020-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-07 | 30.81K shares derived: sum of 2 quarters · filed 2020-05-07 | 557.89K shares 10-Q · filed 2020-05-07 | 444.04K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 30.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06 | 557.89K shares 10-Q · filed 2020-02-06 | 444.04K shares derived: sum of 3 quarters · filed 2020-02-06 | 677.89K shares derived: sum of 4 quarters · filed 2020-02-06 |
| 2019-09-30 | 527.08K shares 10-Q · filed 2019-11-07 | 413.23K shares derived: sum of 2 quarters · filed 2019-11-07 | 647.08K shares derived: sum of 3 quarters · filed 2019-11-07 | 647.08K shares derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | -113.85K shares derived: 10-K 12 month − 3 quarters · filed 2019-08-28 | 120.00K shares derived: sum of 2 quarters · filed 2019-08-28 | 120.00K shares derived: sum of 3 quarters · filed 2019-08-28 | 353.85K shares 10-K · filed 2019-08-28 |
| 2019-03-31 | 233.85K shares 10-Q · filed 2019-05-09 | 233.85K shares derived: sum of 2 quarters · filed 2019-05-09 | 467.71K shares derived: sum of 3 quarters · filed 2019-05-09 | 471.77K shares derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07 | 233.85K shares 10-Q · filed 2019-02-07 | 237.92K shares derived: sum of 3 quarters · filed 2019-02-07 | 349.76K shares derived: sum of 4 quarters · filed 2019-02-07 |
| 2018-09-30 | 233.85K shares 10-Q · filed 2018-11-08 | 237.92K shares derived: sum of 2 quarters · filed 2018-11-08 | 349.76K shares derived: sum of 3 quarters · filed 2018-11-08 | 399.76K shares derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | 4.06K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-30 | 115.91K shares derived: sum of 2 quarters · filed 2018-08-30 | 165.91K shares derived: sum of 3 quarters · filed 2018-08-30 | 238.25K shares 10-K · filed 2018-08-30 |
| 2018-03-31 | 111.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | 161.84K shares derived: sum of 2 quarters · filed 2018-05-09 | 234.19K shares 10-Q · filed 2018-05-09 | 234.36K shares derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | 122.34K shares 10-Q · filed 2018-02-08 | 122.52K shares derived: sum of 3 quarters · filed 2018-02-08 | 137.25K shares derived: sum of 4 quarters · filed 2018-02-08 |
| 2017-09-30 | 72.34K shares 10-Q · filed 2017-11-08 | 72.52K shares derived: sum of 2 quarters · filed 2017-11-08 | 87.25K shares derived: sum of 3 quarters · filed 2017-11-08 | 104.03K shares derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-06-30 | 177.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-05 | 14.91K shares derived: sum of 2 quarters · filed 2017-09-05 | 31.68K shares derived: sum of 3 quarters · filed 2017-09-05 | 54.81K shares 10-K · filed 2017-09-05 |
| 2017-03-31 | 14.73K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-04 | 31.51K shares derived: sum of 2 quarters · filed 2017-05-04 | 54.63K shares 10-Q · filed 2017-05-04 | 84.23K shares derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-12-31 | 16.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | 39.90K shares 10-Q · filed 2017-02-08 | 69.50K shares derived: sum of 3 quarters · filed 2017-02-08 | 77.67K shares derived: sum of 4 quarters · filed 2017-02-08 |
| 2016-09-30 | 23.12K shares 10-Q · filed 2016-11-09 | 52.73K shares derived: sum of 2 quarters · filed 2016-11-09 | 60.89K shares derived: sum of 3 quarters · filed 2016-11-09 | 65.89K shares derived: sum of 4 quarters · filed 2016-11-09 |
| 2016-06-30 | 29.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-06 | 37.77K shares derived: sum of 2 quarters · filed 2016-09-06 | 42.77K shares derived: sum of 3 quarters · filed 2016-09-06 | 56.47K shares 10-K · filed 2016-09-06 |
| 2016-03-31 | 8.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-05 | 13.16K shares derived: sum of 2 quarters · filed 2016-05-05 | 26.87K shares 10-Q · filed 2016-05-05 | |
| 2015-12-31 | 5.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05 | 18.70K shares 10-Q · filed 2016-02-05 | ||
| 2015-09-30 | 13.71K shares 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | 48.97K shares 10-K · filed 2015-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |